Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $13.18, for a total value of $251,210.80. Following the completion of the sale, the chief operating officer owned 494,920 shares of the company’s stock, valued at approximately $6,523,045.60. This trade represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total transaction of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total transaction of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total transaction of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Trading Down 0.8%

ADPT stock traded down $0.11 on Wednesday, hitting $13.28. 1,550,271 shares of the company’s stock traded hands, compared to its average volume of 2,051,436. Adaptive Biotechnologies Corporation has a 1-year low of $6.68 and a 1-year high of $20.76. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -33.20 and a beta of 2.19. The stock has a fifty day moving average of $16.44 and a 200-day moving average of $15.90.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Guggenheim lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. BTIG Research boosted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at $28,000. Sound Income Strategies LLC purchased a new position in shares of Adaptive Biotechnologies during the third quarter valued at $30,000. EverSource Wealth Advisors LLC raised its position in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the period. Assetmark Inc. raised its position in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth about $51,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.